Oritavancin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Oritavancin" in English language version.

refsWebsite

Global rank English rank

31nih.gov

4^th place

19doi.org

2^nd place

4semanticscholar.org

11^th place

8^th place

3web.archive.org

1^st place

2europa.eu

68^th place

117^th place

2fda.gov

447^th place

338^th place

1worldcat.org

5^th place

1bioworld.com

low place

1fiercebiotech.com

low place

8,828^th place

bioworld.com

Okudaira T (9 May 2014). "The Daily Biopharmaceutical News Source". BioWorld. Retrieved 6 June 2014.

doi.org

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med. 31 (4): 449–465. doi:10.53854/liim-3104-4. PMC 10705857. PMID 38075413.
Domenech O, Francius G, Tulkens PM, Van Bambeke F, Dufrêne Y, Mingeot-Leclercq MP (September 2009). "Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1788 (9): 1832–1840. doi:10.1016/j.bbamem.2009.05.003. PMID 19450541.
Crandon J, Nicolau DP (June 2008). "Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens". Future Microbiology. 3 (3): 251–263. doi:10.2217/17460913.3.3.251. PMID 18505390.
Brade KD, Rybak JM, Rybak MJ (March 2016). "Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections". Infectious Diseases and Therapy. 5 (1): 1–15. doi:10.1007/s40121-016-0103-4. PMC 4811835. PMID 26831328.
Heine HS, Bassett J, Miller L, Bassett A, Ivins BE, Lehoux D, et al. (September 2008). "Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax". Antimicrobial Agents and Chemotherapy. 52 (9): 3350–3357. doi:10.1128/AAC.00360-08. PMC 2533456. PMID 18606841.
Yan Q, Karau MJ, Patel R (October 2018). "In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection". Diagnostic Microbiology and Infectious Disease. 92 (2): 155–157. doi:10.1016/j.diagmicrobio.2018.05.010. PMID 29885758. S2CID 47010590.
Yan Q, Karau MJ, Patel R (August 2018). "In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci". Diagnostic Microbiology and Infectious Disease. 91 (4): 348–350. doi:10.1016/j.diagmicrobio.2018.03.008. PMID 29678300. S2CID 5021157.
Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, et al. (December 2010). "Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing". Antimicrobial Agents and Chemotherapy. 54 (12): 5369–5371. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.
Zhanel GG, Schweizer F, Karlowsky JA (April 2012). "Oritavancin: mechanism of action". Clinical Infectious Diseases. 54 (Suppl 3): S214 – S219. doi:10.1093/cid/cir920. PMID 22431851.
Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ (1 June 2015). "β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium". The Journal of Antimicrobial Chemotherapy. 70 (6): 1738–1743. doi:10.1093/jac/dkv007. PMC 4542582. PMID 25645208.
Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E (May 2019). "In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci". The Journal of Antimicrobial Chemotherapy. 74 (5): 1300–1305. doi:10.1093/jac/dkz010. PMID 30753495.
Lagatolla C, Mehat JW, La Ragione RM, Luzzati R, Di Bella S (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium". Antibiotics. 11 (10): 1334. doi:10.3390/antibiotics11101334. PMC 9598191. PMID 36289992.
Di Cecco C, Monticelli J, Di Bella S, Di Maso V, Luzzati R (August 2023). "Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment". Journal of Chemotherapy. 36 (1): 31–34. doi:10.1080/1120009X.2023.2247205. PMID 37602423. S2CID 261048377.
Cruz I, Di Bella S, D'Oria M, Lagatolla C, Martins MC, Monteiro C (22 October 2024). "Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection". Pharmaceutics. 16 (11): 1348. doi:10.3390/pharmaceutics16111348. ISSN 1999-4923. PMC 11597391.
Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN (March 2012). "Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010". Antimicrobial Agents and Chemotherapy. 56 (3): 1639–1642. doi:10.1128/AAC.06067-11. PMC 3294904. PMID 22183169.
Mendes RE, Sader HS, Flamm RK, Jones RN (June 2014). "Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide". The Journal of Antimicrobial Chemotherapy. 69 (6): 1579–1581. doi:10.1093/jac/dku016. PMID 24505091.
Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF (November 2009). "Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates". Antimicrobial Agents and Chemotherapy. 53 (11): 4762–4771. doi:10.1128/AAC.00952-09. PMC 2772347. PMID 19738026.
Kmeid J, Kanafani ZA (2015). "Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review". Core Evidence. 10: 39–47. doi:10.2147/CE.S51284. PMC 4334198. PMID 25709561.
Chastain DB, Davis A (April 2019). "Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review". International Journal of Antimicrobial Agents. 53 (4): 429–434. doi:10.1016/j.ijantimicag.2018.11.023. PMID 30537532. S2CID 54475167.

europa.eu

ema.europa.eu

"Orbactiv EPAR". 17 September 2018.
"EPAR summary: Orbactiv" (PDF). European Medicines Agency. Archived from the original (PDF) on 19 June 2018. Retrieved 12 February 2017.

fda.gov

"FDA approves Orbactiv to treat skin infections" (Press release). U.S. Food and Drug Administration (FDA). 6 August 2014. Archived from the original on 8 August 2014.
"FDA approves Orbactiv to treat skin infections" (Press release). U.S. Food and Drug Administration (FDA). 6 August 2014. Archived from the original on 8 August 2014.

fiercebiotech.com

"Biotechs pick up slack in antibiotics development". 17 May 2011.

nih.gov

pubmed.ncbi.nlm.nih.gov

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med. 31 (4): 449–465. doi:10.53854/liim-3104-4. PMC 10705857. PMID 38075413.
Domenech O, Francius G, Tulkens PM, Van Bambeke F, Dufrêne Y, Mingeot-Leclercq MP (September 2009). "Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1788 (9): 1832–1840. doi:10.1016/j.bbamem.2009.05.003. PMID 19450541.
Scheinfeld N (January 2007). "A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus". Journal of Drugs in Dermatology. 6 (1): 97–103. PMID 17373167.
Crandon J, Nicolau DP (June 2008). "Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens". Future Microbiology. 3 (3): 251–263. doi:10.2217/17460913.3.3.251. PMID 18505390.
Brade KD, Rybak JM, Rybak MJ (March 2016). "Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections". Infectious Diseases and Therapy. 5 (1): 1–15. doi:10.1007/s40121-016-0103-4. PMC 4811835. PMID 26831328.
Heine HS, Bassett J, Miller L, Bassett A, Ivins BE, Lehoux D, et al. (September 2008). "Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax". Antimicrobial Agents and Chemotherapy. 52 (9): 3350–3357. doi:10.1128/AAC.00360-08. PMC 2533456. PMID 18606841.
Yan Q, Karau MJ, Patel R (October 2018). "In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection". Diagnostic Microbiology and Infectious Disease. 92 (2): 155–157. doi:10.1016/j.diagmicrobio.2018.05.010. PMID 29885758. S2CID 47010590.
Yan Q, Karau MJ, Patel R (August 2018). "In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci". Diagnostic Microbiology and Infectious Disease. 91 (4): 348–350. doi:10.1016/j.diagmicrobio.2018.03.008. PMID 29678300. S2CID 5021157.
Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, et al. (December 2010). "Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing". Antimicrobial Agents and Chemotherapy. 54 (12): 5369–5371. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.
Zhanel GG, Schweizer F, Karlowsky JA (April 2012). "Oritavancin: mechanism of action". Clinical Infectious Diseases. 54 (Suppl 3): S214 – S219. doi:10.1093/cid/cir920. PMID 22431851.
Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ (1 June 2015). "β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium". The Journal of Antimicrobial Chemotherapy. 70 (6): 1738–1743. doi:10.1093/jac/dkv007. PMC 4542582. PMID 25645208.
Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E (May 2019). "In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci". The Journal of Antimicrobial Chemotherapy. 74 (5): 1300–1305. doi:10.1093/jac/dkz010. PMID 30753495.
Lagatolla C, Mehat JW, La Ragione RM, Luzzati R, Di Bella S (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium". Antibiotics. 11 (10): 1334. doi:10.3390/antibiotics11101334. PMC 9598191. PMID 36289992.
Di Cecco C, Monticelli J, Di Bella S, Di Maso V, Luzzati R (August 2023). "Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment". Journal of Chemotherapy. 36 (1): 31–34. doi:10.1080/1120009X.2023.2247205. PMID 37602423. S2CID 261048377.
Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN (March 2012). "Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010". Antimicrobial Agents and Chemotherapy. 56 (3): 1639–1642. doi:10.1128/AAC.06067-11. PMC 3294904. PMID 22183169.
Mendes RE, Sader HS, Flamm RK, Jones RN (June 2014). "Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide". The Journal of Antimicrobial Chemotherapy. 69 (6): 1579–1581. doi:10.1093/jac/dku016. PMID 24505091.
Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF (November 2009). "Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates". Antimicrobial Agents and Chemotherapy. 53 (11): 4762–4771. doi:10.1128/AAC.00952-09. PMC 2772347. PMID 19738026.
Kmeid J, Kanafani ZA (2015). "Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review". Core Evidence. 10: 39–47. doi:10.2147/CE.S51284. PMC 4334198. PMID 25709561.
Chastain DB, Davis A (April 2019). "Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review". International Journal of Antimicrobial Agents. 53 (4): 429–434. doi:10.1016/j.ijantimicag.2018.11.023. PMID 30537532. S2CID 54475167.

ncbi.nlm.nih.gov

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med. 31 (4): 449–465. doi:10.53854/liim-3104-4. PMC 10705857. PMID 38075413.
Brade KD, Rybak JM, Rybak MJ (March 2016). "Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections". Infectious Diseases and Therapy. 5 (1): 1–15. doi:10.1007/s40121-016-0103-4. PMC 4811835. PMID 26831328.
Heine HS, Bassett J, Miller L, Bassett A, Ivins BE, Lehoux D, et al. (September 2008). "Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax". Antimicrobial Agents and Chemotherapy. 52 (9): 3350–3357. doi:10.1128/AAC.00360-08. PMC 2533456. PMID 18606841.
Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, et al. (December 2010). "Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing". Antimicrobial Agents and Chemotherapy. 54 (12): 5369–5371. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.
Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ (1 June 2015). "β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium". The Journal of Antimicrobial Chemotherapy. 70 (6): 1738–1743. doi:10.1093/jac/dkv007. PMC 4542582. PMID 25645208.
Lagatolla C, Mehat JW, La Ragione RM, Luzzati R, Di Bella S (September 2022). "In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium". Antibiotics. 11 (10): 1334. doi:10.3390/antibiotics11101334. PMC 9598191. PMID 36289992.
Cruz I, Di Bella S, D'Oria M, Lagatolla C, Martins MC, Monteiro C (22 October 2024). "Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection". Pharmaceutics. 16 (11): 1348. doi:10.3390/pharmaceutics16111348. ISSN 1999-4923. PMC 11597391.
Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN (March 2012). "Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010". Antimicrobial Agents and Chemotherapy. 56 (3): 1639–1642. doi:10.1128/AAC.06067-11. PMC 3294904. PMID 22183169.
Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF (November 2009). "Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates". Antimicrobial Agents and Chemotherapy. 53 (11): 4762–4771. doi:10.1128/AAC.00952-09. PMC 2772347. PMID 19738026.
Kmeid J, Kanafani ZA (2015). "Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review". Core Evidence. 10: 39–47. doi:10.2147/CE.S51284. PMC 4334198. PMID 25709561.

dailymed.nlm.nih.gov

"Orbactiv- oritavancin injection, powder, lyophilized, for solution". DailyMed. Retrieved 18 December 2020.
"Kimyrsa- oritavancin diphosphate injection, powder, lyophilized, for solution". DailyMed. Retrieved 31 March 2021.

semanticscholar.org

api.semanticscholar.org

Yan Q, Karau MJ, Patel R (October 2018). "In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection". Diagnostic Microbiology and Infectious Disease. 92 (2): 155–157. doi:10.1016/j.diagmicrobio.2018.05.010. PMID 29885758. S2CID 47010590.
Yan Q, Karau MJ, Patel R (August 2018). "In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci". Diagnostic Microbiology and Infectious Disease. 91 (4): 348–350. doi:10.1016/j.diagmicrobio.2018.03.008. PMID 29678300. S2CID 5021157.
Di Cecco C, Monticelli J, Di Bella S, Di Maso V, Luzzati R (August 2023). "Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment". Journal of Chemotherapy. 36 (1): 31–34. doi:10.1080/1120009X.2023.2247205. PMID 37602423. S2CID 261048377.
Chastain DB, Davis A (April 2019). "Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review". International Journal of Antimicrobial Agents. 53 (4): 429–434. doi:10.1016/j.ijantimicag.2018.11.023. PMID 30537532. S2CID 54475167.

web.archive.org

"FDA approves Orbactiv to treat skin infections" (Press release). U.S. Food and Drug Administration (FDA). 6 August 2014. Archived from the original on 8 August 2014.
"FDA approves Orbactiv to treat skin infections" (Press release). U.S. Food and Drug Administration (FDA). 6 August 2014. Archived from the original on 8 August 2014.
"EPAR summary: Orbactiv" (PDF). European Medicines Agency. Archived from the original (PDF) on 19 June 2018. Retrieved 12 February 2017.

worldcat.org

search.worldcat.org

Cruz I, Di Bella S, D'Oria M, Lagatolla C, Martins MC, Monteiro C (22 October 2024). "Vascular Graft Impregnation with a Fosfomycin/Oritavancin Combination to Prevent Early Infection". Pharmaceutics. 16 (11): 1348. doi:10.3390/pharmaceutics16111348. ISSN 1999-4923. PMC 11597391.